
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+6
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune discovered aducanumab for Alzheimers disease together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmunes Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinsons disease, the anti-tau antibody BIIB076 for Alzheimers disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials
Biotech,human antibodies,alzheimer's disease,parkinsons's disease,als,cardiomyopathy,type 2 diabetes,drug discovery,drug development,neuroscience,and therapeutics
Neurimmune ag operates in the Pharmaceutical manufacturing industry.
Neurimmune ag's revenue is 11m - 100m
Neurimmune ag has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.